| First Author | Morodomi Y | Year | 2020 |
| Journal | Blood | Volume | 135 |
| Issue | 25 | Pages | 2292-2301 |
| PubMed ID | 32157300 | Mgi Jnum | J:301274 |
| Mgi Id | MGI:6503692 | Doi | 10.1182/blood.2019003770 |
| Citation | Morodomi Y, et al. (2020) Mechanisms of anti-GPIbalpha antibody-induced thrombocytopenia in mice. Blood 135(25):2292-2301 |
| abstractText | Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by antibody-mediated platelet destruction. Different mechanisms have been suggested to explain accelerated platelet clearance and impaired thrombopoiesis, but the pathophysiology of ITP has yet to be fully delineated. In this study, we tested 2 mouse models of immune-mediated thrombocytopenia using the rat anti-mouse GPIbalpha monoclonal antibody 5A7, generated in our laboratory. After a single IV administration of high-dose (2 mg/kg) 5A7, opsonized platelets were rapidly cleared from the circulation into the spleen and liver; this was associated with rapid upregulation of thrombopoietin (TPO) messenger RNA. In contrast, subcutaneous administration of low-dose 5A7 (0.08-0.16 mg/kg) every 3 days gradually lowered the platelet count; in this case, opsonized platelets were observed only in the spleen, and TPO levels remained unaltered. Interestingly, in both models, the 5A7 antibody was found on the surface of, as well as internalized to, bone marrow megakaryocytes. Consequently, platelets generated in the chronic phase of repeated subcutaneous 5A7 administration model showed reduced GPIbalpha membrane expression on their surface. Our findings indicate that evaluation of platelet surface GPIbalpha relative to platelet size may be a useful marker to support the diagnosis of anti-GPIbalpha antibody-induced ITP. |
